Structure Therapeutics, Inc.’s (NASDAQ:GPCR) stock climbed approximately 35% on September 29, 2023, after the company announced phase Ib data for its obesity and diabetes drug, GSBR-1290. Structure reported GSBR-1290 helped participants reduce up to 4.5 kgs of body weight on average after four weeks of treatment.
Share this post
Structure Thera's shares surge after phase I…
Share this post
Structure Therapeutics, Inc.’s (NASDAQ:GPCR) stock climbed approximately 35% on September 29, 2023, after the company announced phase Ib data for its obesity and diabetes drug, GSBR-1290. Structure reported GSBR-1290 helped participants reduce up to 4.5 kgs of body weight on average after four weeks of treatment.